We are live on ! Find out more
VNDA icon

Vanda Pharmaceuticals
VNDA

99 hedge funds and large institutions have $348M invested in Vanda Pharmaceuticals in 2013 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 44 increasing their positions, 19 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

132% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 19

102% more call options, than puts

Call options by funds: $40.3M | Put options by funds: $20M

86% more capital invested

Capital invested by funds: $187M → $348M (+$160M)

86% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 14

13% more funds holding

Funds holding: 88 → 99 (+11)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
99
Holders Change
+11
Holders Change %
+12.5%
% of All Funds
3.21%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
26
Increased
44
Reduced
19
Closed
14
Calls
$40.3M
Puts
$20M
Net Calls
+$20.3M
Net Calls Change
+$8.83M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$25.3M
2
Wells Fargo
Wells Fargo
California
+$13.4M
3
PA
Perceptive Advisors
New York
+$9.28M
4
BBA
Baker Bros. Advisors
New York
+$8.81M
5
DM
Deerfield Management
New York
+$8.76M

Top Sellers

Rank Fund Capital Flow
1
CCM
Consonance Capital Management
New York
-$9.85M
2
NI
Numeric Investors
Massachusetts
-$7.95M
3
First Eagle Investment Management
First Eagle Investment Management
New York
-$7.88M
4
BIM
Bogle Investment Management
Massachusetts
-$3.94M
5
VM
VHCP Management
New York
-$3.17M
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Investments
101
Two Sigma Investments
New York
– -$1.49M -184,290 Closed
Susquehanna International Group
102
Susquehanna International Group
Pennsylvania
– -$1.38M -129,035 Closed
EMG
103
Ellington Management Group
Connecticut
– -$949K -117,400 Closed
SIM
104
Spark Investment Management
New York
– -$926K -115,000 Closed
Balyasny Asset Management
105
Balyasny Asset Management
Illinois
– -$848K -105,000 Closed
ISL
106
Ingalls & Snyder LLC
New York
– -$694K -85,900 Closed
SM
107
Sabby Management
Florida
– -$607K -56,843 Closed
Los Angeles Capital Management
108
Los Angeles Capital Management
California
– -$340K -42,058 Closed
OC
109
Oppenheimer & Co
New York
– -$323K -40,000 Closed
CCMH
110
Cornerstone Capital Management Holdings
New York
– -$232K -28,604 Closed
MNBTD
111
Moody National Bank Trust Division
Texas
– -$208K -25,755 Closed
BNP Paribas Financial Markets
112
BNP Paribas Financial Markets
France
– -$97.6K -12,078 Closed
MWNA
113
Marshall Wace North America
New York
– -$96K -11,856 Closed
1 2 3 4
5

VNDA Hedge Fund Activity: Q3 2013 in Review

99 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q3 2013, worth a combined $348M — up 86% from $187M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new VNDA positions and 14 closed out — a net gain of 12 holders — while 44 added to existing stakes and 19 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $25.3M. The largest seller was Consonance Capital Management, cutting an estimated $9.85M.

  • 99 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q3 2013, up from 88 in Q2 2013.
  • Funds reported $348M of Vanda Pharmaceuticals stock for Q3 2013, up 86% quarter-over-quarter.
  • 26 funds opened new Vanda Pharmaceuticals positions in Q3 2013 and 14 closed out, a net change of +12 holders.
  • The largest Vanda Pharmaceuticals buyer in Q3 2013 was Fidelity Investments, an estimated $25.3M added.
  • The largest Vanda Pharmaceuticals seller in Q3 2013 was Consonance Capital Management, an estimated $9.85M sold.

Based on aggregated 13F filings for Q3 2013.